This may have resulted from the reduced sensitivity of AML cells to venetoclax observed in CM relative to MCM, mediated by a switch from BCL-2- to BCL-XL-dependent cell survival that has a less pronounced effect on navitoclax32. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.